An Open-Label Study to Assess the Effect of Different Grades of Renal Impairment in Japanese Patients With Type 2 Diabetes Mellitus on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP1941 Relative to Type 2 Diabetes Mellitus Patients With Normal Renal Function.
Phase of Trial: Phase I
Latest Information Update: 15 May 2015
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Astellas Pharma
- 24 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Apr 2010 New trial record